Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +2.69% | +5.36% | -5.14% |
Financials (USD)
Sales 2024 * | 42.75K | Sales 2025 * | 4.12M | Capitalization | 507M |
---|---|---|---|---|---|
Net income 2024 * | -283M | Net income 2025 * | -305M | EV / Sales 2024 * | 6,013 x |
Net cash position 2024 * | 250M | Net cash position 2025 * | 284M | EV / Sales 2025 * | 54.2 x |
P/E ratio 2024 * |
-1.77
x | P/E ratio 2025 * |
-1.79
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.82% |
Latest transcript on Allogene Therapeutics, Inc.
1 day | +1.71% | ||
1 week | +4.03% | ||
Current month | +7.61% | ||
1 month | -27.03% | ||
3 months | -26.67% | ||
Current year | -7.48% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
David Chang
FOU | Founder | 64 | 18-03-31 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 18-04-30 |
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.54% | 2 M€ | -25.75% | ||
0.08% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 3.04 | +2.36% | 881 384 |
24-05-02 | 2.97 | +1.71% | 1,400,492 |
24-05-01 | 2.92 | +5.80% | 2,585,419 |
24-04-30 | 2.76 | -2.82% | 2,151,154 |
24-04-29 | 2.84 | -1.73% | 3,060,517 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.48% | 507M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- ALLO Stock